Sanofi and DKSH have announced a strategic partnership to improve access to cardiovascular treatments in Malaysia, Singapore, and Thailand, and diabetes treatments in Singapore and Thailand. This collaboration combines Sanofi’s scientific expertise with DKSH’s regional commercial capabilities to address the growing burden of chronic diseases in Southeast Asia.
The partnership comes as healthcare systems in the ASEAN region face challenges from ageing populations and increasing demand for quality care. Cardiovascular disease and diabetes are among the most prevalent non-communicable diseases in the area. By leveraging DKSH’s end-to-end services, the collaboration aims to provide integrated, value-driven healthcare solutions tailored to local needs.
Eric Mansion, General Manager Pharma Southeast Asia and India at Sanofi, stated, “This partnership with DKSH is a meaningful step in strengthening how we serve patients. With DKSH’s proven healthcare expertise and strong commercial capabilities in Southeast Asia, we can broaden access to established treatments, enhance the experience for healthcare professionals and patients, and stay agile as market needs evolve.”
Patrik Grande, Global Head of Business Unit Healthcare at DKSH, expressed enthusiasm for the partnership, highlighting DKSH’s capabilities in customer insights and omni-channel engagement. “Through this collaboration, we aim to help improve access to treatment as part of our mission to deliver better healthcare for all,” he said.
The collaboration is set to ensure continuity of care, strengthen stakeholder partnerships, and support sustainable healthcare outcomes across the region, reflecting a shared commitment to patient-centric care.
